Givastomig  (Synonyms: TJ-CD4B; ABL111; TJ033721)

Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma^[1].

IgG1-kappa-[scFv-lambda-heavy]2

Human IgG1 kappa, Isotype Control

Human

TNFRSF9 & CLDN18

Givastomig binds to human CLDN18.2 VLP and human 4-1BB protein with high affinity, achieving an equilibrium dissociation constant (K_D = 1.698 × 10^-10/9.88 × 10^-9 M)^[1].
Givastomig (0.001-1000 nM, 1 h) specifically binds to CLDN18.2 (EC₅₀ = 0.13 nM) and does not cross-react with its isoform CLDN18.1 expressed in normal lung tissue^[1].
Givastomig (0.001-1000 nM, 30 min) shows a stronger binding affinity to all the tested CHO-K1-hCLDN18.2 expressing high, medium and even low level of CLDN18.2 than the control monoclonal antibody^[1].
Givastomig (6 h) is co-cultured with NF-κB/4-1BB reporter Jurkat cell lines, which induces strong NF-κB signaling activation, while when co-cultured with CLDN18.2+ cells, it does not activate NF-κB signaling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Givastomig (4 mg/kg, i.v., Biweekly) conditionally activates 4-1BB+ T cells in the tumor microenvironment by targeting CLDN18.2-positive tumor cells, thereby generating a potent anti-tumor immune response and durable immune memory in mouse models^[1].
Givastomig (0.4-10 mg/kg, i.v., once a week, for a total of three cycles) shows that the anti-tumor activity in colon carcinoma mouse models is dose-dependent^[1].
Givastomig (10-100 mg/kg, i.v., once a week, for 5 times) demonstrates excellent safety in cynomolgus monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3604  [NCBI] & 51208  [NCBI]

Q07011 & P56856

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

201.929 kDa

2762499-30-7

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv]2-lambda-heavy

• 
  Immobilized 4-1BB/TNFRSF9 Protein, Human (HY-P7125) can bind Givastomig. The EC₅₀ for this effect is 1.795 ng/mL.
• 
  Immobilized Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, HY-P78368) can bind Givastomig. The EC₅₀ for this effect is 1.744 ng/mL.

• [1]. Gao J, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023 Jun;11(6):e006704.  [Content Brief]

  [2]. Ku G, et al. A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2025 Jun 30:10.1158/1078-0432.CCR-24-4280.  [Content Brief]